TREATMENT OF ORAL CHRONIC GRAFT-VS-HOST DISEASE WITH CLOBETASOL: CASE REPORT

• Published in: Oral surgery, oral medicine, oral pathology and oral radiology Vol. 129; no. 1; p. e89
• Main Authors: VALENTIM, BARBARA BARRETO PACHECO, DE ASSIS RAMOS, GABRIELA, LOBO, CAMILA BRANDÃO, SILVA, TAÍSA DOMINGUES BERNARDES, ANTUNES, HELITON SPINDOLA
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.01.2020
• ISSN: 2212-4403; 2212-4411
• DOI: 10.1016/j.oooo.2019.06.367

Graft-vs-host disease (GVHD) is the main complication of allogeneic hematopoietic stem cells transplantation. A 29-year-old Brazilian man was diagnosed as having severe aplastic anemia and submitted to allogeneic HSCT in October 2013. He developed systemic chronic GVHD, including the oral cavity (lichenoid lesions in right and left buccal mucosa and labial hyperchromia and was treated with mycophenolate mofetil, tacrolimus, cyclosporine, and dexamethasone solution [mouthwash]). Upon stabilization of chronic GVHD in the oral cavity, the patient displayed gingival atrophy and erythema (12-21/33-42) on July 27, 2017. Dexamethasone mouthwash and tacrolimus ointment was unsuccessful. On November 11, 2017, the patient was instructed to use clobetasol gel 0.05% on individual tray 4 times/d/15 min. The total regression of gingival chronic GVHD was observed within 22 days. On January 1, 2018, the patient presented relapse of gingival erythema (12-21) with worsening of condition due to treatment discontinuation. We observed that clobetasol on individual tray was effective in this case.